Clinical Trial Results:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism
Summary
|
|
EudraCT number |
2020-003380-26 |
Trial protocol |
DK NO FR DE HU IT |
Global end of trial date |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Apr 2023
|
First version publication date |
27 Apr 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
TCP-304
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04701203 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ascendis Pharma Bone Diseases A/S
|
||
Sponsor organisation address |
Tuborg Boulevard 12, Hellerup, Denmark, DK 2900
|
||
Public contact |
Clinical Trial Information Desk , Ascendis Pharma Bone Diseases A/S, 45 70222244, clinhelpdesk@ascendispharma.com
|
||
Scientific contact |
Clinical Trial Information Desk , Ascendis Pharma Bone Diseases A/S, 45 70222244, clinhelpdesk@ascendispharma.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
15 Jul 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
12 Jan 2022
|
||
Global end of trial reached? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the treatment effect of daily TransCon PTH on serum calcium levels, and therapeutic doses of active vitamin D (i.e., calcitriol or alfacalcidol) and calcium at 26 weeks of treatment.
|
||
Protection of trial subjects |
Written informed consent was obtained from all subjects prior to enrollment into the trial, as dictated by the Declaration of Helsinki.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Dec 2020
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
3 Years | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 30
|
||
Country: Number of subjects enrolled |
Canada: 21
|
||
Country: Number of subjects enrolled |
Norway: 1
|
||
Country: Number of subjects enrolled |
Denmark: 11
|
||
Country: Number of subjects enrolled |
Germany: 1
|
||
Country: Number of subjects enrolled |
Hungary: 7
|
||
Country: Number of subjects enrolled |
Italy: 11
|
||
Worldwide total number of subjects |
82
|
||
EEA total number of subjects |
31
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
72
|
||
From 65 to 84 years |
10
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
Overall, 82 subjects were enrolled and dosed. Enrollment of subjects occurred in seven countries: Canada, Denmark, Germany, Italy, Hungary, Norway, and the United States. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 106 subjects were screened and 84 of these met eligibility criteria and were enrolled into the study. Two subjects randomized to TransCon PTH were not treated. A total of 82 subjects were therefore included in the ITT and the Safety analysis populations. | |||||||||||||||||||||
Pre-assignment period milestones
|
||||||||||||||||||||||
Number of subjects started |
84 [1] | |||||||||||||||||||||
Number of subjects completed |
82 | |||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
||||||||||||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 1 | |||||||||||||||||||||
Reason: Number of subjects |
Adverse event, non-fatal: 1 | |||||||||||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 84 subjects met eligibility criteria and were enrolled into the study. However, 2 subjects randomized to TransCon PTH were not treated. |
||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
26 Week Blinded Treatment Period (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
TransCon PTH | |||||||||||||||||||||
Arm description |
Once daily subcutaneous administration of TransCon PTH at a starting dose of 18 mcg/day | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
TransCon PTH
|
|||||||||||||||||||||
Investigational medicinal product code |
ACP-014
|
|||||||||||||||||||||
Other name |
Palopegteriparatide
|
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
TransCon PTH drug product was supplied as a clear solution containing palopegteriparatide with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection. All subjects were initially prescribed TransCon PTH 18 μg PTH(1-34)/d and were individually and progressively titrated to an optimal dose (allowable range 6–60 μg/d) in increments of 3 μg/d. Titration of study drug and conventional therapy was performed according to a protocol-specified algorithm guided by serum calcium values.
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
Placebo for TransCon PTH drug product was supplied as a clear solution containing placebo liquid to match the investigational product in a pre-filled pen intended for subcutaneous injection.
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TransCon PTH
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Once daily subcutaneous administration of TransCon PTH at a starting dose of 18 mcg/day | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
TransCon PTH
|
||
Reporting group description |
Once daily subcutaneous administration of TransCon PTH at a starting dose of 18 mcg/day | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product |
|
|||||||||||||
End point title |
Efficacy - Primary Endpoint | ||||||||||||
End point description |
The proportion of subjects with albumin-adjusted serum calcium measured within 4 weeks prior to and on Week 26 visit within the normal range (8.3 to 10.6 mg/dL), and independence from active vitamin D within 4 weeks prior to Week 26 visit (i.e., all daily standing dose of active vitamin D equal to zero AND use of PRN ≤7 days during the 4 weeks), and independence from therapeutic doses of calcium within 4 weeks prior to Week 26 visit (i.e., average daily standing dose of elemental calcium ≤600 mg AND use of PRN doses on ≤7 days during the 4 weeks) and, no increase in prescribed study drug within 4 weeks prior to Week 26 visit.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
26 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary efficacy endpoint | ||||||||||||
Statistical analysis description |
For the primary efficacy endpoint, the Cochran–Mantel Haenszel test stratified by etiology of hypoparathyroidism (postsurgical or other) was used to compare the proportion of participants meeting the composite primary endpoint in the TransCon PTH versus placebo groups. Participants without week 26 albumin-adjusted serum calcium or with >25% (ie, >7 days) missing diary data of active vitamin D or elemental calcium during the 4 weeks before week 26 were considered non-responders.
|
||||||||||||
Comparison groups |
TransCon PTH v Placebo
|
||||||||||||
Number of subjects included in analysis |
82
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HPES - Symptom - Physical Domain Score | ||||||||||||
End point description |
Hypoparathyroidism Patient Experience Scale (HPES) - Symptom - Physical Domain score change from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism related physical symptoms.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 26
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
HPES - Symptom - Physical Domain Score | ||||||||||||
Statistical analysis description |
ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
|
||||||||||||
Comparison groups |
TransCon PTH v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.0038 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HPES - Symptom - Cognitive Domain Score | ||||||||||||
End point description |
Hypoparathyroidism Patient Experience Scale (HPES) - Symptom - Cognitive Domain score change from baseline. A decrease in HPES score denotes an improvement in hypoparathyroidism related cognitive symptoms.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 26
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
HPES - Symptom - Cognitive Domain Score | ||||||||||||
Statistical analysis description |
ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
|
||||||||||||
Comparison groups |
Placebo v TransCon PTH
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.0055 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HPES - Impact - Physical Functioning Domain Score | ||||||||||||
End point description |
Hypoparathyroidism Patient Experience Scale (HPES) - Impact - Physical Functioning Domain score change from baseline. A decrease in HPES score denotes an improvement in health-related quality of life.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 26
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
HPES - Impact - Physical Functioning Domain Score | ||||||||||||
Statistical analysis description |
ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
|
||||||||||||
Comparison groups |
TransCon PTH v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.0046 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
HPES - Impact - Daily Life Domain Score | ||||||||||||
End point description |
Hypoparathyroidism Patient Experience Scale (HPES) - Impact - Daily Life Domain score change from baseline. A decrease in HPES score denotes an improvement in health-related quality of life.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 26
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
HPES - Impact - Daily Life Domain Score | ||||||||||||
Statistical analysis description |
ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
|
||||||||||||
Comparison groups |
TransCon PTH v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.0061 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
SF-36 – Physical Functioning Subscale Score | ||||||||||||
End point description |
36-item Short Form Survey (SF-36) – Physical Functioning Subscale Score change from baseline. An increase in SF-36 score denotes an improvement in health-related quality of life.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 26
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
SF-36 – Physical Functioning Subscale Score | ||||||||||||
Statistical analysis description |
ANCOVA model with unequal variance was used to analyze the key secondary Endpoints. The change from baseline is variable of interest at week 26 and was included in the model as response variables. Treatment assignment and etiology of hypoparathyroidism were entered as fixed effects and baseline value of the variable of interest was entered as a covariate.
|
||||||||||||
Comparison groups |
TransCon PTH v Placebo
|
||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
P-value |
= 0.0347 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
26 Week Blinded Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TransCon PTH
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Once daily subcutaneous administration of TransCon PTH at a starting dose of 18 mcg/day | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Once daily subcutaneous administration of placebo for TransCon PTH to mimick the dose of investigational product | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 Mar 2021 |
The protocol amendment was to address comments and recommendations from Health Authorities and provide clarification on the trial. |
||
10 Jun 2021 |
The protocol amendment provided clarification on the trial and addressed a Health Authority comment. |
||
03 Aug 2021 |
The protocol amendment updated the primary and secondary efficacy endpoints based on FDA recommendation. |
||
20 Dec 2021 |
The protocol amendment updated the primary and secondary efficacy endpoints based on FDA recommendation. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/36271471 |